Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 4:39 PM ET

Capital Markets

Company Overview of Flagship Ventures

Company Overview

Flagship Ventures is a private equity and venture capital firm specializing in incubation, seed stage, early, later and growth stage investments. The firm prefers to invest in the healthcare including biotherapeutics, life sciences, medical technologies, and biological discoveries leading to new therapies, advanced analysis for improved medicine, chemistries and small molecule drugs, nanotechnology for medicine; energy efficiency; bioenergy; sustainability, focusing on energy, water, and agriculture/nutrition; and clean technology sector. The firm seeks to invest in Midwest, focusing on investing nationally. It seeks to initially invest between $500,000 and $5 million, with a typical investm...

One Memorial Drive

7th Floor

Cambridge, MA 02142

United States

Founded in 2000

Phone:

617-868-1888

Fax:

617-868-1115

Key Executives for Flagship Ventures

Co-Founder, Senior Managing Partner, and Chief Executive Officer
Age: 52
Co-Founder and Managing Partner
Age: 58
Chief Financial Officer and Controller
Age: 44
Chief Operating Officer, Partner, and General Partner
Age: 62
Partner and Chief Business Officer
Age: 61
Compensation as of Fiscal Year 2015.

Flagship Ventures Key Developments

Flagship Ventures Launches Rubius Therapeutics

Flagship Ventures announced it has launched Rubius Therapeutics, to develop functionalized red blood cells for the treatment of autoimmune conditions, metabolic diseases, cancer, and other serious diseases. The company has made an initial capital commitment of $25 million to enable Rubius to enter clinical testing of its novel therapeutic modality. Rubius is pioneering Red-Cell Therapeutics. RCTs are a new treatment modality and possess pharmacodynamic and pharmacokinetic advantages over traditional therapeutics, in part due to their natural ability to engage and modulate the immune system and circulate for extended periods in the body One of the diseases Rubius intends to initially target is phenylketonuria (PKU), a disease of metabolism that affects as many as one in 13,000 births in the U.S. and is responsible for about 300 new cases each year. People born with PKU have a genetic defect that leaves them unable to break down a particular amino acid, one of the building blocks of proteins. Left untreated, the amino acid, phenylalanine, builds up in the body and causes severe developmental problems and long-term health issues. Newborns are routinely tested for this genetic disease within days of birth. Currently, the most effective treatment for PKU is a strict diet that lowers the amount of phenylalanine in the body. Rubius has developed and pre-clinically validated a Red-Cell Therapeutic capable of enzymatically reducing phenylalanine levels in human serum. By continually lowering phenylalanine levels in the bloodstream, RCT therapy promises to allow PKU patients to live normally without extremely restrictive diets.

Flagship Ventures Launches Evelo Therapeutics to Develop Microbiome Therapies for Cancer

Flagship Ventures announced it has launched Evelo Therapeutics, a new company focused on leveraging the power of the microbiome to develop novel therapies for cancer, with an initial capital commitment of $35 million. Evelo is pioneering Oncobiotic therapeutics, a new modality in cancer therapy based on the cancer microbiome. Evelo is the first company to systematically identify, characterize and understand the biology of cancer-associated bacteria (CAB) and bacterial immune activators (BIAs), providing new insights into cancer metabolism and immuno-oncology. Evelo's Oncobiotic platform would treat cancer through unprecedented therapeutic modalities. Evelo's novel approaches leverage tumor-microenvironment modifications that can be mediated by the microbiome to disrupt tumor metabolism and the interactions between the tumor and surrounding tissue. Evelo is also exploring novel Oncobiotic approaches that can leverage the ability of bacteria to uniquely and powerfully activate the immune system to fight cancer. In this respect, Evelo is developing a next-generation approach to immuno-oncology that goes beyond check-point inhibitors and CAR-T cell therapies.

Flagship Ventures Presents at BIO-Europe 2015, Nov-02-2015 04:00 PM

Flagship Ventures Presents at BIO-Europe 2015, Nov-02-2015 04:00 PM. Venue: Munich, Germany. Speakers: Jeremy Springhorn, Partner, Corporate Development.

Similar Private Companies By Industry

Company Name Region
Royal Alliance Associates, Inc. United States
Merity, Anderson & Associates United States
Summer Highlands Limited United States
Trinity Capital LLC United States
Fairmount Partners LP United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 15, 2016
Blend Therapeutics, Inc.
Private Placement
December 9, 2015
Rubius Therapeutics, Inc.
Private Placement
November 21, 2015
VL32 Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Flagship Ventures, please visit www.flagshipventures.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.